ATXS(ATXS)
ATXS
ANALYST COVERAGE8 analysts
HOLD
▲ +59.0%upside to target
L $13.00
Med $20.00consensus
H $26.00Key MetricsTTM
Market Cap$718.13M
Revenue TTM$706.0K
Net Income TTM-$124.03M
Free Cash Flow-$120.32M
Gross Margin100.0%
Operating Margin-19335.7%
Net Margin-17568.0%
Return on Equity-45.0%
Return on Assets-45.6%
Debt / Equity0.02
Current Ratio10.78
EPS TTM$-2.14
PRICE
Prev Close
12.58
Open
12.58
Day Range—
52W Range3.56 – 13.29
3.56
13.29
93% of range
VOLUME & SIZE
Avg Volume
1.1M
FUNDAMENTALS
P/E Ratio
-5.9x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.22
Market-like
TECHNICAL
RSI (14)
48
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
ATXS News
About
No description available.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Christopher J. MorabitoChief Medical Officer
Andrew A. KomjathyChief Commercial Officer
Benjamin S. HarshbargerChief Legal Officer
John RueschSenior Vice President of Pharmaceutical Sciences & Technical Operations
Noah ClauserChief Financial Officer & Treasurer
Andrea L. MatthewsChief Business Officer
Jill C. MilneCo-Founder, Chief Executive Officer, President & Director
Keri McGrailChief Human Resources Officer
Rafif DagherSenior Vice President and Head of Discovery, Nonclinical Development & Translational Research